Abstract
Background
Over the past few years, microarray-based gene expression profiling has been a promising approach in predicting cancer classification and prognosis outcomes [1] .In most cases, cancer diagnosis depends on using a complex combination of clinical and histopathological data. However, it is often difficult or impossible to recognize the tumour type in some atypical instances [2] . In the past decade, DNA microarray technologies have had a great impact on cancer genome research; this technology measures the expression level for thousands of gene expressions simultaneously [3, 4, 5] . It is a powerful tool in the study of functional genomes [6, 7] . Large scale profiling of genetic expression and genomic alternations using DNA microarrays can reveal the differences between normal and malignant cells, genetic and cellular changes at each stage of tumour progression and metastasis, as well as the difference among cancers of different origins. Cancer classification is becoming the critical basis in patient therapy. Researchers are continuously developing and applying the most accurate classification algorithms based on gene expression profiles of patients.
Prostate cancer and leukemia are very common cancers in the United States. In 2007 alone, approximately 24 ,800 new cases and 12,320 deaths among males were attributed to leukemia. Among males age 40 and below, leukemia is the most common fatal cancer. Meanwhile, 19,440 new cases and 9,470 deaths among females were attributed to leukemia, and it is the leading cause of cancer death among females below age 20. Acute lymphocytic leukemia (ALL) is the most common cancer in children ages 0 to 14. As for prostate cancer, it alone accounts for almost 29% (218,890) of incident cases in men in 2007. For men age 80 and older, prostate cancer is the second most common cause of cancer death. Based on cases diagnosed between 1996 and 2002, an estimated 91% of these new cases of prostate cancer are expected to be diagnosed at local or regional stages, for which 5-year relative survival approaches 100% [8] .Therefore, the identification of significant genes is of fundamental and practical interest. The examination of the top ranking genes may be helpful in confirming recent discoveries in cancer research or in suggesting new methods to be explored.
There are several machine learning techniques such as k-nearest neighbours, clustering methods [9] , self organizing maps (SOM) [10] , Genetic Algorithms [11] , back-propagation neural network [12, 13] probabilistic neural network, decision tree [14] , random forest [15] , support vector machines (SVM) [16, 17] , multicategory support vector machines (MC-SVM) [1] , Bayesian network [18, 19] , and the module-network [20, 21] that have been applied in cancer classification. Among these techniques, SVM is touted as having the best accuracy in the prediction of cancer classification [1, 22] . Of the classification algorithms mentioned above, most suffer from a high dimensional input space problem due to a large amount of DNA microarray gene expression data. Reducing the number of genes used for analysis while maintaining a consistently high accuracy is one method to avoid this problem. Likewise, how to reduce the number of genes needed for analysis while then increasing the prediction accuracy becomes a key challenge.
In this paper, we propose a new method to select genes that can produce a very high prediction accuracy of classification outcomes and use the second task to improve traditional BPNN. We hypothesize that samples (i.e. patient's profiles) which are incorrectly classified may significantly affect the selection of significant genes. By removing these samples, one should have a better chance of targeting relevant genes and, therefore, increasing classification performance. We call this approach the multi-task support vector sample learning (MTSVSL) technique. To validate the benefits of this new method, we applied our approach to both leukemia and prostate cancers. Our method produces a super classification performance for small gene subsets by selecting genes that have plausible relevance to cancer diagnosis.
Materials and methods

Theoretical basis of the SVS technique
The SVS technique is briefly described as follows. A binary SVM attempts to find a hyperplane which maximizes the "margin" between two classes (+1/-1). Let 
 > 0 would be used, and these points are support vectors. The support vectors lay close to the separating hyperplane (shown in figure 2 ). i  represents non-negative Lagrange multipliers, and it is used to discriminate every piece of training data which has different influences to the hyperplane in high dimension feature spaces. To explain the meanings of i  , we first maximize the Lagrange problem:
 means that the ith data that has no influence to the hyperplane; therefore, this sample is correctly classified by the hyperplane (such as point A in infer that these support vectors should contain the desired strong classification information. By extracting only the samples (such as point B) located on the hyper plane, we can run a gene selection algorithm that better identifies biologically relevant genes.
We then applied our method to two microarray datasets of leukemia and prostate cancers. We found 32 support vector samples in 72 leukemia samples and 44 support vector samples in 102 prostate cancer samples. After reducing the original samples by almost 55%, we used these samples to find the most informative genes through gene selection algorithms.
Multi-task learning concept
The concept of multi-task learning (MTL) can be referred to [23] . The principle goal of multi-task learning is to improve the performance of classifier. The multi-task learning can be considered as an inductive transfer mechanism. The inductive transfer is leverage additional sources of information to improve the performance of learning on current task. Considering some variables which cannot be used as useful inputs because they will be missing for making predictions; however, they may be useful as extra outputs. Instead of discarding these variables, MTL get the inductive transfer benefit from discarded variables by using them as extra output.
To take back-propagation neural network as example, the figure 2 shows the three back-propagation network structures. In Figure 2, (A) is a standard back-propagation network and only one main task as output. (B) adds the extra variable as the extra input to learn in the main task. (C) presents that the network uses the extra variable as extra output to learn in parallel with main task and second task and it's a common structure for MTL. MTL uses the inductive bias contained in training signals of related tasks. It is implemented by having extra outputs and learn task in parallel while using shared perception (see fig. 2 C) , what is learned for each task can help other task to learn better. We propose a new approach, multi-task support vector sample learning (MTSVSL), which combines the SVS method with MTL concept together to classify the gene expression data. The pseudo code is displayed in Table 1 . By this approach, classifier need to simultaneously learn two tasks, the main task is "which kind of sample is this?" and the second task is "is this sample a support vector sample?". We propose to categorize the samples into four classes, namely: 1) the sample which is both class 1 and support vector sample.
2) the sample which is both class 2 and support vector sample.
3) the sample which is class 1 but not support vector sample. 4) the sample which is class 2 but not support vector sample. The support vector sample's feature is mentioned in section 2.1. Most classifier just learned the main task; however in our experiment, we find that the bias which is generated by learning the second task can improve the classifier performance. The ratio of these two biases is set as
. The ratio of second bias cannot be set too high since it may harm the performance of main task. 
Gene selection method
Gene selection is widely used to select target genes in the diagnosis of cancer. One of the prime goals of gene selection is to avoid the over-fitting problems caused by the high dimensions and relatively small number of samples of microarray data. Theoretically, in cancer classification, only informative genes which are highly related to particular classes (or subtypes) should be selected. In this study, we use signal-to-noise ratio (SNR) as our gene selection method [24, 25] . For each gene, we normalized the gene expression data by subtracting the mean and then dividing by the standard deviation of the expression value. Every sample is labeled with {+1,-1} as either a normal or a cancer sample. We can use the formula (3) to calculate each gene's F score.
The  and  are mean and standard deviation of samples in each class (either +1or -1) individually. We rank these genes with F score and then select the top 25, 50, 100, and 150 gene set as the features.
Back propagation neural network (BPNN) classifier
The typical back-propagation neural network consists of one input layer, one output layer, and at least one hidden layer. The number of neurons presented in the input and output layer depends on the number of variables. Furthermore, the number of neurons used for the hidden layer is optimized by trial-and-error training assays. The behaviour of a back-propagation neural network is mainly determined by the transfer functions of its neurons. Here, we develop the BPNN codes using the Matlab NN tool box. The tan-sigmoid transfer function (formula 4) and log-sigmoid transfer function (formula 5) were applied for hidden and output neurons individually.
We set the output threshold to be 0.5. If the output value is over 0.5, the sample will be set as a normal sample; otherwise, the sample will be as an abnormal sample.
Cross validation method
The main purpose of cross validation methods is used to estimate the model performance based on the re-sampling technique. This method separates data into a training dataset and a validation dataset. A model is trained by the training dataset and then verified by the validation dataset. The following two common cross validation methods are usually used.
(1). K-fold cross validation method: this method divides the data into k subsets of equal or approximately size. It chose one subset from k subsets as the validation dataset for verifying the model, the remainder (k-1) dataset as the model's training dataset. The cross validation process is then repeated K times with each of the K subsets used only once as the validation data. The K results from the folds then can be averaged to produce a single estimation of the model performance.
(2). Leave-one-out cross validation method: As the name of this method, if we have n dataset, this method extracts one dataset as the validation dataset; the remainder (n-1) is used as the training dataset. Repeat this approach until all dataset was used. The results can be averaged to produce a single estimation of the model performance.
As Ambroise and McLachlan pointed out that the performance of classification maybe overestimated by using Leave-out-out method, therefore, we verify our experiment using random average 3-fold method. This random average 3-fold method randomly separates dataset into 3-fold and repeat validation 100 times in order to get the impartial performance results for our model.
Results and discussions
In this section, we compare the results from MTSVSL with the results from the basic BPNN. To demonstrate the benefits of the MTSVSL method, we experiment it for leukemia and prostate cancer gene expression data. We applied random average 3-fold cross validation method to get the impartial performance results. In this experimentation the gene selection method is SNR
Application of MTSVSL to the leukemia dataset
In the first set of experiment, we carried out a comparison between our MTSVSL method and BPNN method on the leukemia data. BPNN method has a high accuracy (94%) in the smaller gene number and a lower accuracy (89%) in 100 and 150 genes. Our MTSVSL generates a better accuracy with a 96% in the smaller gene number and a 91% in 100 and 150 genes. Our model improves the accuracy approximately 1% to 3% (see table 2 ). In general, the average sensitivity and specificity of BPNN is improved by MTSVSL which then improve the accuracy. One reason of this improvement is that the BPNN is very sensitive to selected genes and the higher number of genes (100 and 150 genes) may contain lower score genes. Therefore, the performance of traditional BPNN approach is worse in higher number of genes. Our MTSVSL method, however, is less affected by the higher number of genes. 
Application of MTSVSL to the prostate cancer dataset
In the second set of experiment, we carried out a comparison between our MTSVSL method and BPNN method on the prostate cancer data. Due to the prostate cancer is considered as a more difficult data to be classified. Traditional BPNN method has an average accuracy of 83% in the range of gene number. Our MTSVSL generates a better accuracy with an 86% average that is above 3% better. Apparently, MTSVSL method can improve all classification performance (sensitivity, specificity, and accuracy) in all the range of gene numbers selected. 
Conclusions
Gene selection methods are critical in order to avoid over fitting problems which usually was caused by high dimensional input spaces. Traditional gene selection approaches, however, do not consider the quality of the samples. We proposed and applied a new support vector sampling method. We call this new method as support vector sampling (SVS). It first extracts the significant samples (i.e. support vector samples located only on support vectors) then use these support vector samples to select significant genes using SNR gene selection method. Then we develop a new classification technique by combining the concept of support vector sampling and Multi-task learning, we called it MTSVSL. We let the basic BPNN to learn more than one task and regulate these learning errors to improve the performance of basic BPNN. This novel approach can improve BPNN's classification performance metrics (accuracy, sensitivity, and specificity) with a small set of genes selected.
We demonstrate experimentally that the genes selected by our MTSVSL method yield superior classification performance with leukemia and prostate cancer gene expression datasets. Our proposed MTSVSL method is a novel approach that is expedient and can produce very good performance in cancer diagnosis and clinical outcome prediction. Due to the successful applying our method to both leukemia and prostate cancer gene expression datasets, we intend to further explore this application in other cancer types as well as in some interest diseases in the near future.
